Concepts (311)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Helicobacter Infections | 62 | 2022 | 1307 | 3.960 |
Why?
|
| Helicobacter pylori | 62 | 2022 | 1367 | 3.790 |
Why?
|
| Crohn Disease | 6 | 2023 | 292 | 1.820 |
Why?
|
| Colitis, Ulcerative | 5 | 2023 | 215 | 1.480 |
Why?
|
| Inflammatory Bowel Diseases | 4 | 2023 | 326 | 1.370 |
Why?
|
| Antibodies, Bacterial | 16 | 2017 | 412 | 1.260 |
Why?
|
| Stomach Neoplasms | 5 | 2022 | 577 | 1.250 |
Why?
|
| Abdominal Pain | 7 | 2014 | 315 | 0.960 |
Why?
|
| Prevalence | 28 | 2022 | 2694 | 0.700 |
Why?
|
| Breath Tests | 14 | 2006 | 182 | 0.650 |
Why?
|
| Cross-Sectional Studies | 20 | 2022 | 3807 | 0.590 |
Why?
|
| Immunoglobulin G | 11 | 2017 | 790 | 0.540 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 77 | 0.520 |
Why?
|
| Adult | 55 | 2023 | 31238 | 0.510 |
Why?
|
| Stomach Ulcer | 7 | 2007 | 94 | 0.490 |
Why?
|
| Seroepidemiologic Studies | 12 | 2017 | 165 | 0.490 |
Why?
|
| Gastroesophageal Reflux | 3 | 2008 | 333 | 0.480 |
Why?
|
| Male | 65 | 2023 | 64763 | 0.480 |
Why?
|
| Family | 3 | 2017 | 583 | 0.480 |
Why?
|
| Adolescent | 34 | 2022 | 20818 | 0.470 |
Why?
|
| Fissure in Ano | 1 | 2015 | 6 | 0.470 |
Why?
|
| Gastrointestinal Diseases | 6 | 2012 | 336 | 0.470 |
Why?
|
| Female | 63 | 2023 | 70550 | 0.440 |
Why?
|
| Socioeconomic Factors | 18 | 2012 | 896 | 0.430 |
Why?
|
| Gastroscopy | 5 | 2022 | 98 | 0.430 |
Why?
|
| Diet | 3 | 2007 | 1100 | 0.420 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 61 | 0.400 |
Why?
|
| Urea | 10 | 2002 | 219 | 0.400 |
Why?
|
| Alendronate | 4 | 2001 | 22 | 0.390 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 12 | 2017 | 784 | 0.390 |
Why?
|
| Middle Aged | 46 | 2018 | 28511 | 0.390 |
Why?
|
| Humans | 86 | 2023 | 130854 | 0.380 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 85 | 0.380 |
Why?
|
| Child | 35 | 2022 | 26215 | 0.380 |
Why?
|
| Surveys and Questionnaires | 15 | 2014 | 4017 | 0.370 |
Why?
|
| Obesity | 3 | 2017 | 2387 | 0.370 |
Why?
|
| Risk Factors | 20 | 2018 | 10978 | 0.360 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 409 | 0.360 |
Why?
|
| Aged | 35 | 2018 | 20970 | 0.360 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 331 | 0.350 |
Why?
|
| Gastritis | 8 | 2007 | 372 | 0.340 |
Why?
|
| Bone Density | 1 | 2014 | 369 | 0.340 |
Why?
|
| Peptic Ulcer | 6 | 2015 | 150 | 0.330 |
Why?
|
| Sex Factors | 8 | 2015 | 1342 | 0.320 |
Why?
|
| Child, Preschool | 23 | 2017 | 15016 | 0.310 |
Why?
|
| Duodenal Ulcer | 6 | 2001 | 126 | 0.310 |
Why?
|
| Incidence | 6 | 2018 | 3336 | 0.300 |
Why?
|
| Age Distribution | 6 | 2018 | 424 | 0.300 |
Why?
|
| Enzyme Inhibitors | 3 | 2007 | 568 | 0.290 |
Why?
|
| Young Adult | 7 | 2018 | 10040 | 0.280 |
Why?
|
| Bhutan | 3 | 2017 | 21 | 0.280 |
Why?
|
| Gastric Mucosa | 7 | 2001 | 492 | 0.260 |
Why?
|
| Aged, 80 and over | 14 | 2017 | 6797 | 0.260 |
Why?
|
| Child Day Care Centers | 3 | 2002 | 24 | 0.250 |
Why?
|
| Texas | 9 | 2018 | 3635 | 0.250 |
Why?
|
| Italy | 6 | 2015 | 111 | 0.240 |
Why?
|
| Life Style | 2 | 2007 | 446 | 0.240 |
Why?
|
| Diseases in Twins | 2 | 1998 | 88 | 0.240 |
Why?
|
| Retrospective Studies | 9 | 2023 | 17673 | 0.240 |
Why?
|
| Amoxicillin | 3 | 1996 | 117 | 0.240 |
Why?
|
| Dyspepsia | 3 | 2015 | 106 | 0.230 |
Why?
|
| Host-Pathogen Interactions | 1 | 2007 | 254 | 0.230 |
Why?
|
| Age Factors | 12 | 2011 | 2841 | 0.220 |
Why?
|
| Prospective Studies | 7 | 2017 | 6448 | 0.210 |
Why?
|
| Bacterial Proteins | 4 | 2015 | 940 | 0.210 |
Why?
|
| Hepatitis A | 2 | 2003 | 28 | 0.210 |
Why?
|
| Bismuth | 3 | 1993 | 84 | 0.200 |
Why?
|
| Hepatitis A Virus, Human | 1 | 2003 | 9 | 0.200 |
Why?
|
| Saliva | 2 | 2002 | 125 | 0.200 |
Why?
|
| Gastrointestinal Agents | 1 | 2023 | 63 | 0.200 |
Why?
|
| Vitamins | 1 | 2023 | 112 | 0.190 |
Why?
|
| Urease | 3 | 2006 | 73 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2011 | 300 | 0.190 |
Why?
|
| Logistic Models | 5 | 2017 | 1805 | 0.180 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2007 | 497 | 0.180 |
Why?
|
| Time Factors | 8 | 2018 | 6217 | 0.180 |
Why?
|
| Vitamin D | 1 | 2023 | 199 | 0.180 |
Why?
|
| Naproxen | 1 | 2001 | 19 | 0.170 |
Why?
|
| Odds Ratio | 4 | 2007 | 1215 | 0.170 |
Why?
|
| Cohort Studies | 8 | 2015 | 5095 | 0.160 |
Why?
|
| Gastrostomy | 1 | 2001 | 86 | 0.160 |
Why?
|
| Drug Therapy, Combination | 6 | 2000 | 1170 | 0.160 |
Why?
|
| Recurrence | 5 | 2007 | 1486 | 0.160 |
Why?
|
| Anti-Ulcer Agents | 2 | 1999 | 115 | 0.160 |
Why?
|
| Proton Pump Inhibitors | 2 | 2007 | 280 | 0.150 |
Why?
|
| Omeprazole | 2 | 1996 | 101 | 0.150 |
Why?
|
| Sensitivity and Specificity | 7 | 2008 | 2113 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 568 | 0.150 |
Why?
|
| Minority Groups | 1 | 2001 | 258 | 0.150 |
Why?
|
| Salicylates | 3 | 1993 | 54 | 0.140 |
Why?
|
| Antigens, Bacterial | 3 | 2015 | 315 | 0.140 |
Why?
|
| Tetracycline | 3 | 1993 | 75 | 0.140 |
Why?
|
| Infant | 7 | 2023 | 13299 | 0.140 |
Why?
|
| Body Mass Index | 3 | 2017 | 1681 | 0.140 |
Why?
|
| Organometallic Compounds | 3 | 1993 | 111 | 0.140 |
Why?
|
| Cluster Analysis | 2 | 2017 | 416 | 0.140 |
Why?
|
| Urban Health | 1 | 2018 | 83 | 0.140 |
Why?
|
| Emigration and Immigration | 1 | 2018 | 81 | 0.130 |
Why?
|
| Educational Status | 5 | 2007 | 274 | 0.130 |
Why?
|
| Bahrain | 1 | 2017 | 3 | 0.130 |
Why?
|
| Registries | 3 | 2018 | 1617 | 0.130 |
Why?
|
| Carbon Isotopes | 6 | 2002 | 229 | 0.120 |
Why?
|
| Fasting | 2 | 2001 | 306 | 0.120 |
Why?
|
| Beverages | 1 | 1996 | 99 | 0.120 |
Why?
|
| Hot Temperature | 1 | 1996 | 141 | 0.120 |
Why?
|
| Penicillins | 1 | 1996 | 153 | 0.120 |
Why?
|
| Food Preferences | 1 | 1996 | 113 | 0.120 |
Why?
|
| Geographic Mapping | 1 | 2015 | 15 | 0.120 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 169 | 0.120 |
Why?
|
| Schools | 1 | 2017 | 234 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 189 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 1998 | 290 | 0.110 |
Why?
|
| Students | 1 | 2017 | 248 | 0.110 |
Why?
|
| Gastric Emptying | 2 | 2014 | 78 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 5 | 2001 | 2564 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2015 | 81 | 0.110 |
Why?
|
| Metronidazole | 4 | 2001 | 162 | 0.110 |
Why?
|
| Nausea | 1 | 2014 | 83 | 0.100 |
Why?
|
| Social Environment | 1 | 1994 | 114 | 0.100 |
Why?
|
| Social Class | 4 | 2007 | 206 | 0.100 |
Why?
|
| Gastroparesis | 1 | 2014 | 69 | 0.100 |
Why?
|
| Russia | 2 | 2007 | 38 | 0.100 |
Why?
|
| Dental Auxiliaries | 1 | 1992 | 2 | 0.100 |
Why?
|
| Dentists | 1 | 1992 | 7 | 0.100 |
Why?
|
| Radiation Dosage | 1 | 2013 | 137 | 0.100 |
Why?
|
| Japan | 3 | 2003 | 166 | 0.100 |
Why?
|
| Safety-net Providers | 1 | 2013 | 86 | 0.090 |
Why?
|
| Occupational Diseases | 1 | 1992 | 77 | 0.090 |
Why?
|
| Chi-Square Distribution | 4 | 2011 | 563 | 0.090 |
Why?
|
| Malaysia | 2 | 2012 | 17 | 0.090 |
Why?
|
| Cephalosporins | 1 | 1992 | 136 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2015 | 887 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2008 | 2924 | 0.090 |
Why?
|
| Follow-Up Studies | 5 | 2007 | 5199 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2015 | 1236 | 0.080 |
Why?
|
| Cross-Over Studies | 3 | 2001 | 324 | 0.080 |
Why?
|
| Sweden | 2 | 2000 | 37 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2023 | 12913 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2015 | 1448 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 894 | 0.070 |
Why?
|
| Sex Distribution | 2 | 2002 | 315 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2014 | 550 | 0.070 |
Why?
|
| Serologic Tests | 2 | 2003 | 125 | 0.070 |
Why?
|
| Carbon Dioxide | 3 | 1999 | 274 | 0.070 |
Why?
|
| Hypertension | 1 | 2017 | 1354 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 37 | 0.070 |
Why?
|
| Twins, Dizygotic | 2 | 2000 | 46 | 0.070 |
Why?
|
| Africa | 1 | 2007 | 140 | 0.060 |
Why?
|
| United States | 7 | 2015 | 11865 | 0.060 |
Why?
|
| Korea | 2 | 1997 | 32 | 0.060 |
Why?
|
| Biopsy | 4 | 1999 | 1243 | 0.060 |
Why?
|
| Twins, Monozygotic | 2 | 2000 | 125 | 0.060 |
Why?
|
| Risk Reduction Behavior | 1 | 2007 | 146 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2012 | 712 | 0.060 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 3040 | 0.060 |
Why?
|
| Education | 1 | 2006 | 111 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2012 | 3393 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2005 | 232 | 0.050 |
Why?
|
| Czech Republic | 1 | 2003 | 11 | 0.050 |
Why?
|
| Double-Blind Method | 4 | 2000 | 1639 | 0.050 |
Why?
|
| Citric Acid | 2 | 2001 | 45 | 0.050 |
Why?
|
| Water Supply | 1 | 2002 | 26 | 0.050 |
Why?
|
| Hygiene | 1 | 2002 | 24 | 0.050 |
Why?
|
| Neoplasms | 1 | 1997 | 2955 | 0.050 |
Why?
|
| Louisiana | 1 | 2002 | 137 | 0.040 |
Why?
|
| Equipment Design | 2 | 2001 | 542 | 0.040 |
Why?
|
| Comorbidity | 1 | 2007 | 1587 | 0.040 |
Why?
|
| Antitrichomonal Agents | 1 | 2001 | 10 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2000 | 731 | 0.040 |
Why?
|
| Erythema | 1 | 2001 | 28 | 0.040 |
Why?
|
| Psychometrics | 1 | 2005 | 671 | 0.040 |
Why?
|
| Etidronic Acid | 1 | 2000 | 10 | 0.040 |
Why?
|
| Nurse's Role | 1 | 2001 | 34 | 0.040 |
Why?
|
| Cellulitis | 1 | 2001 | 62 | 0.040 |
Why?
|
| Clarithromycin | 1 | 2001 | 133 | 0.040 |
Why?
|
| Equipment Failure | 1 | 2001 | 132 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2000 | 110 | 0.040 |
Why?
|
| Wound Infection | 1 | 2001 | 56 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2001 | 236 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2001 | 237 | 0.040 |
Why?
|
| Nuclear Family | 1 | 2000 | 50 | 0.040 |
Why?
|
| Esophagus | 2 | 1999 | 233 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2000 | 86 | 0.040 |
Why?
|
| Patient Selection | 2 | 2001 | 723 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1996 | 227 | 0.040 |
Why?
|
| Spouses | 1 | 2000 | 70 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2000 | 74 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2001 | 229 | 0.040 |
Why?
|
| Antibodies | 1 | 2000 | 320 | 0.040 |
Why?
|
| Endoscopes, Gastrointestinal | 1 | 1999 | 8 | 0.040 |
Why?
|
| Statistics, Nonparametric | 3 | 2011 | 426 | 0.040 |
Why?
|
| Health Behavior | 1 | 2002 | 389 | 0.040 |
Why?
|
| Sialic Acids | 1 | 1999 | 17 | 0.040 |
Why?
|
| Atrophy | 2 | 1996 | 246 | 0.040 |
Why?
|
| Fiber Optic Technology | 1 | 1999 | 44 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 1999 | 52 | 0.040 |
Why?
|
| Lactose | 1 | 1999 | 55 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2000 | 1493 | 0.040 |
Why?
|
| Lactoferrin | 1 | 1999 | 76 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 548 | 0.030 |
Why?
|
| Physicians, Family | 1 | 1998 | 37 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2006 | 896 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2007 | 3694 | 0.030 |
Why?
|
| Duodenoscopy | 1 | 1997 | 16 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2001 | 1405 | 0.030 |
Why?
|
| Sucrose | 1 | 1997 | 36 | 0.030 |
Why?
|
| Lansoprazole | 1 | 1996 | 27 | 0.030 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 1996 | 30 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 391 | 0.030 |
Why?
|
| Feces | 1 | 2000 | 722 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1999 | 1618 | 0.030 |
Why?
|
| Alcoholism | 1 | 1999 | 244 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2010 | 8509 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 1996 | 88 | 0.030 |
Why?
|
| Orphanages | 1 | 1996 | 7 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 1999 | 292 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1996 | 143 | 0.030 |
Why?
|
| Housing | 1 | 1996 | 74 | 0.030 |
Why?
|
| Aspirin | 1 | 1997 | 215 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2000 | 765 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 1125 | 0.030 |
Why?
|
| Child, Hospitalized | 1 | 1996 | 78 | 0.030 |
Why?
|
| Virulence | 1 | 2015 | 271 | 0.030 |
Why?
|
| Gastroenterology | 1 | 1998 | 221 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1892 | 0.030 |
Why?
|
| Hepatitis C, Chronic | 1 | 1999 | 366 | 0.030 |
Why?
|
| Pregnancy | 1 | 2007 | 7402 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2000 | 2303 | 0.030 |
Why?
|
| Child Rearing | 1 | 1994 | 27 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 115 | 0.030 |
Why?
|
| Regression Analysis | 2 | 1992 | 760 | 0.030 |
Why?
|
| Topography, Medical | 1 | 2013 | 6 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 1996 | 251 | 0.030 |
Why?
|
| Crowding | 1 | 2013 | 12 | 0.030 |
Why?
|
| Ranitidine | 1 | 1992 | 31 | 0.020 |
Why?
|
| Drinking Water | 1 | 2012 | 15 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1991 | 41 | 0.020 |
Why?
|
| Mesalamine | 1 | 2011 | 6 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 751 | 0.020 |
Why?
|
| Failure to Thrive | 1 | 2011 | 87 | 0.020 |
Why?
|
| Campylobacter Infections | 1 | 1990 | 33 | 0.020 |
Why?
|
| Steroids | 1 | 2011 | 170 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1380 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2013 | 277 | 0.020 |
Why?
|
| Aging | 2 | 1998 | 1257 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2011 | 187 | 0.020 |
Why?
|
| Developing Countries | 1 | 1991 | 303 | 0.020 |
Why?
|
| Medicaid | 1 | 2011 | 251 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2000 | 230 | 0.020 |
Why?
|
| Eructation | 1 | 2007 | 1 | 0.020 |
Why?
|
| Bronchial Spasm | 1 | 2007 | 3 | 0.020 |
Why?
|
| Laryngitis | 1 | 2007 | 7 | 0.020 |
Why?
|
| Hiccup | 1 | 2007 | 6 | 0.020 |
Why?
|
| Proton Pumps | 1 | 2007 | 12 | 0.020 |
Why?
|
| Hoarseness | 1 | 2007 | 13 | 0.020 |
Why?
|
| Pharyngitis | 1 | 2007 | 34 | 0.020 |
Why?
|
| Sialorrhea | 1 | 2007 | 15 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 3400 | 0.010 |
Why?
|
| Cough | 1 | 2007 | 99 | 0.010 |
Why?
|
| Chest Pain | 1 | 2007 | 124 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1994 | 3428 | 0.010 |
Why?
|
| Kazakhstan | 1 | 2002 | 8 | 0.010 |
Why?
|
| Hepatitis A Antibodies | 1 | 2002 | 9 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 2001 | 64 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 197 | 0.010 |
Why?
|
| Patient Compliance | 2 | 1995 | 465 | 0.010 |
Why?
|
| Reference Standards | 1 | 2001 | 232 | 0.010 |
Why?
|
| Occupations | 1 | 2000 | 18 | 0.010 |
Why?
|
| Vietnam | 1 | 2000 | 65 | 0.010 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2000 | 117 | 0.010 |
Why?
|
| Pentagastrin | 1 | 1999 | 5 | 0.010 |
Why?
|
| Temperance | 1 | 1999 | 15 | 0.010 |
Why?
|
| Esophagoscopy | 1 | 2000 | 174 | 0.010 |
Why?
|
| Gastric Acidity Determination | 1 | 1999 | 24 | 0.010 |
Why?
|
| Glucans | 1 | 1999 | 14 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1999 | 140 | 0.010 |
Why?
|
| Citrates | 1 | 1999 | 23 | 0.010 |
Why?
|
| Colonoscopes | 1 | 1999 | 9 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1999 | 98 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1999 | 42 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1999 | 74 | 0.010 |
Why?
|
| Equipment Safety | 1 | 1999 | 34 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 1999 | 72 | 0.010 |
Why?
|
| Colostrum | 1 | 1999 | 58 | 0.010 |
Why?
|
| Information Services | 1 | 1998 | 23 | 0.010 |
Why?
|
| Reference Values | 1 | 1999 | 679 | 0.010 |
Why?
|
| Cattle | 1 | 1999 | 501 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1999 | 325 | 0.010 |
Why?
|
| Acute Disease | 1 | 2000 | 1151 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 1457 | 0.010 |
Why?
|
| Colonoscopy | 1 | 1999 | 241 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1999 | 344 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1999 | 702 | 0.010 |
Why?
|
| Biological Transport | 1 | 1997 | 331 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1996 | 52 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 1324 | 0.010 |
Why?
|
| Observer Variation | 1 | 1996 | 318 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1995 | 351 | 0.010 |
Why?
|
| Genotype | 1 | 2000 | 2606 | 0.010 |
Why?
|
| Twin Studies as Topic | 1 | 1994 | 13 | 0.010 |
Why?
|
| ROC Curve | 1 | 1996 | 607 | 0.010 |
Why?
|
| Causality | 1 | 1994 | 90 | 0.010 |
Why?
|
| Neutrophils | 1 | 1996 | 361 | 0.010 |
Why?
|
| Stomach Diseases | 1 | 1994 | 56 | 0.010 |
Why?
|
| Arkansas | 1 | 1991 | 58 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1991 | 92 | 0.010 |
Why?
|
| India | 1 | 1991 | 244 | 0.010 |
Why?
|
| Campylobacter | 1 | 1990 | 20 | 0.010 |
Why?
|
| Saudi Arabia | 1 | 1990 | 41 | 0.010 |
Why?
|
| Smoking | 1 | 1990 | 923 | 0.000 |
Why?
|
| Animals | 1 | 1999 | 33981 | 0.000 |
Why?
|